
    
      The study will consist of a screening/baseline period of up to 90 days pre-study drug, with a
      12-month (+3 day) treatment period with rapamycin, followed by a post-treatment assessment
      completed within 14 days of the final study drug dose, and a final assessment conducted
      6-months (+14 days) after the final study drug dose. The study duration is not expected to
      exceed 90 weeks for participants.
    
  